News
-
-
PRESS RELEASE
Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Buy recommendation on Jaguar Health Inc (ISIN: US47010C8055) to USD 40 target price post-positive breast cancer trial subgroup results. Plans for FDA approval through pivotal trial and orphan drug designation -
-
PRESS RELEASE
Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset
Jaguar Health, Inc. diversifies treasury holdings with long-term digital store of value through including cryptocurrency as a reserve asset. Company aims to safeguard against inflation and assesses potential benefits for core development programs -
-
-
-
PRESS RELEASE
Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026
Jaguar Health, Inc. extends maturity date of convertible promissory notes in bridge financing. CEO Lisa Conte appreciates investors' support for core programs -
-
PRESS RELEASE
Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer
Enrollment in Jaguar Health's placebo-controlled Phase 2 study for microvillus inclusion disease (MVID) reaches 25%. Crofelemer shows promise in reducing total parenteral nutrition in pediatric patients with MVID and short bowel syndrome, seeking business partnerships for non-dilutive funding
